{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-012483","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.995317+00:00","generated_at":"2026-06-17T01:38:59.665254+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anixa Biosciences and Cleveland Clinic report positive Phase 1 data for breast cancer vaccine","bullets":["Phase 1 trial of triple-negative breast cancer vaccine showed antigen-specific T cell responses at all dose levels.","Trial funded by U.S. Department of Defense; Anixa is exclusive worldwide licensee from Cleveland Clinic.","Participants were tumor-free women with history of TNBC, curatively treated, at high risk of recurrence.","Phase 1a study evaluates safety, MTD, and immune response; not designed to measure recurrence prevention."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-012483","json":"https://secwatch.observer/filing/0001493152-23-012483.json","markdown":"https://secwatch.observer/filing/0001493152-23-012483.md","text":"https://secwatch.observer/filing/0001493152-23-012483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315223012483/0001493152-23-012483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315223012483/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:38:59.665254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}